Voya Investment Management LLC decreased its stake in Horizon Pharma PLC (NASDAQ:HZNP) by 29.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 759,811 shares of the biopharmaceutical company’s stock after selling 315,244 shares during the period. Voya Investment Management LLC owned 0.47% of Horizon Pharma PLC worth $9,019,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. OxFORD Asset Management LLP boosted its position in shares of Horizon Pharma PLC by 10.8% during the 2nd quarter. OxFORD Asset Management LLP now owns 196,748 shares of the biopharmaceutical company’s stock valued at $2,335,000 after purchasing an additional 19,215 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Horizon Pharma PLC by 119.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 6,265,608 shares of the biopharmaceutical company’s stock valued at $74,373,000 after purchasing an additional 3,409,411 shares in the last quarter. Parametric Portfolio Associates LLC boosted its position in shares of Horizon Pharma PLC by 168.4% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 406,617 shares of the biopharmaceutical company’s stock valued at $4,827,000 after purchasing an additional 255,110 shares in the last quarter. California Public Employees Retirement System boosted its position in shares of Horizon Pharma PLC by 4.4% during the 2nd quarter. California Public Employees Retirement System now owns 314,500 shares of the biopharmaceutical company’s stock valued at $3,733,000 after purchasing an additional 13,300 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Horizon Pharma PLC by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 12,982,718 shares of the biopharmaceutical company’s stock valued at $154,105,000 after purchasing an additional 233,443 shares in the last quarter. 82.33% of the stock is owned by institutional investors.

Several equities research analysts recently commented on HZNP shares. Cantor Fitzgerald started coverage on Horizon Pharma PLC in a research report on Friday, June 16th. They set an “overweight” rating and a $13.00 target price on the stock. BidaskClub upgraded Horizon Pharma PLC from a “hold” rating to a “buy” rating in a research report on Saturday, June 24th. Zacks Investment Research upgraded Horizon Pharma PLC from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 11th. Jefferies Group LLC restated a “buy” rating and set a $14.00 target price on shares of Horizon Pharma PLC in a research report on Friday, July 14th. Finally, Piper Jaffray Companies set a $17.00 target price on Horizon Pharma PLC and gave the company a “buy” rating in a research report on Tuesday, July 25th. Five investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Horizon Pharma PLC has a consensus rating of “Buy” and an average target price of $18.00.

Horizon Pharma PLC (NASDAQ:HZNP) opened at 13.54 on Friday. Horizon Pharma PLC has a one year low of $9.45 and a one year high of $21.98. The company’s market cap is $2.21 billion. The firm has a 50-day moving average price of $13.00 and a 200 day moving average price of $12.75.

Horizon Pharma PLC (NASDAQ:HZNP) last posted its earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 earnings per share for the quarter, topping analysts’ consensus estimates of $0.12 by $0.29. Horizon Pharma PLC had a positive return on equity of 22.85% and a negative net margin of 42.40%. The firm had revenue of $289.51 million for the quarter, compared to the consensus estimate of $237.01 million. During the same quarter in the prior year, the business earned $0.56 EPS. The business’s revenue for the quarter was up 12.5% on a year-over-year basis. Equities analysts expect that Horizon Pharma PLC will post $1.07 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/voya-investment-management-llc-sells-315244-shares-of-horizon-pharma-plc-hznp/1617491.html.

About Horizon Pharma PLC

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Institutional Ownership by Quarter for Horizon Pharma PLC (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.